Method of treatment of philadelphia chromosome positive leukemia
US-2016304616-A1 · Oct 20, 2016 · US
Therapeutic agent or treatment method for Philadelphia chromosome-positive (Ph+) acute lymphocytic leukemia (ALL) having IKZF1 mutation
US10314834B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10314834-B2 |
| Application number | US-201615758582-A |
| Country | US |
| Kind code | B2 |
| Filing date | Sep 9, 2016 |
| Priority date | Sep 10, 2015 |
| Publication date | Jun 11, 2019 |
| Grant date | Jun 11, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide derivative and a BCR-ABL tyrosine kinase inhibitor to a patient suffering from Philadelphia chromosome positive lymphocytic leukemia.
First claim
Opening claim text (preview).
We claimed: 1. A pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, comprising a BCR-ABL tyrosine kinase inhibitor and a thalidomide derivative, wherein the thalidomide derivative is lenalidomide and/or pomalidomide, and the BCR-ABL tyrosine kinase inhibitor is at least one selected from the group consisting of imatinib, dasatinib, nilotinib and bostinib. 2. The pharmaceutical composition according to claim 1 , wherein the Philadelphia chromosome positive lymphocytic leukemia has an IKZF1 gene mutation. 3. The pharmaceutical composition according to claim 2 , wherein the IKZF1 gene mutation lacks one or more exons. 4. The pharmaceutical composition according to claim 2 , wherein the IKZF1 gene mutation lacks at least four exons. 5. The pharmaceutical composition according to claim 2 , wherein the IKZF1 gene mutation is a single allelic mutation. 6. The pharmaceutical composition according to claim 1 , wherein the Philadelphia chromosome positive lymphocytic leukemia is Philadelphia chromosome positive acute lymphocytic leukemia.
Assignees
Inventors
Classifications
ortho- or peri-condensed with heterocyclic ring systems · CPC title
Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00 · CPC title
having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin · CPC title
having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol · CPC title
Antineoplastic agents · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10314834B2 cover?
- According to the present invention, there is provided a pharmaceutical composition for treating Philadelphia chromosome positive lymphocytic leukemia, including a thalidomide derivative and BCR-ABL tyrosine kinase inhibitor. According to the present invention there is also provided a method of treating Philadelphia chromosome positive lymphocytic leukemia, including administering a thalidomide …
- Who is the assignee on this patent?
- Univ Yamanashi, Tokai Univ Educational System
- What technology area does this patent fall under?
- Primary CPC classification A61K31/454. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jun 11 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 2 related publications on this page (citations in our corpus or others sharing the same primary CPC).